Eucreas 50mg / 850mg and 50mg / 1000mg film-coated tablets

*
Pharmacy Only: Prescription

Updated on 20 March 2024

File name

Eucreas REG_PIL_05.01.2024_PF24-009_New BRS site.docx.pdf

Reasons for updating

  • Change to section 6 - manufacturer

Free text change information supplied by the pharmaceutical company

New batch release site

Updated on 24 August 2022

File name

Eucreas_REG PIL_PF22-148_07.07.2022_clean IPHA.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

New side effect added: blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, red, round spots under the skin's surface or bruising.

Updated on 24 August 2022

File name

Eucreas_REG SPC_PF22-148_07.07.2022_IPHA.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Cutaneous vasculitis is added as an ADR with frequency “unknown” 

Updated on 26 July 2022

File name

Eucreas_REG PIL_PF22-117_23.06.22 IPHA.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Change in frequency of some side effects

Updated on 26 July 2022

File name

Eucreas_REG SPC_PF21-117_23.06.2022_IPHA.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes to Section 4.8: ‘Abdominal pain renamed as ‘Abdominal pain, including upper. Skin reactions such as rash and dermatitis, were included with the frequency “common”

Updated on 06 July 2021

File name

Eucreas_REG PIL_PF 21-0164_June 2021_Clean.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - interactions with other medicines, food or drink

Updated on 06 July 2021

File name

Eucreas_REG SPC_PF 21-0164_June 2021_IPHA.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 02 September 2020

File name

EUCREAS REG PIL New R89 SKU and Lendava as BRS_May 2020.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - manufacturer

Updated on 15 June 2020

File name

Eucreas REG SPC PF20-112 May 2020 clean.pdf

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Approval of new triplex blister packs

Updated on 28 November 2019

File name

EUCREAS REG PIL Site Transfer September 2019.pdf

Reasons for updating

  • Improved presentation of PIL

Updated on 28 November 2019

File name

Galvus REG PIL PF18-073.pdf

Reasons for updating

  • Improved presentation of PIL

Updated on 28 November 2019

File name

EUCREAS REG PIL Site Transfer September 2019.pdf

Reasons for updating

  • Improved presentation of PIL

Updated on 02 April 2019

File name

Eucreas50-850mg+50-1000mg_REG_SmPC_PF18-0072_clean IPHA.pdf

Reasons for updating

  • File format updated to PDF

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 23 October 2018

File name

EUCREAS_REG_PIL_2215784_R91_WEH_p1_LFT_X-4_IPHA.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 17 May 2018

File name

Eucreas50-850mg+50-1000mg_REG_SmPC_PF18-0072_clean.docx

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 May 2018

File name

Eucreas50-850mg+50-1000mg_REG_SmPC_PF18-0072_clean.docx

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 14 May 2018

File name

Eucreas50-850mg+50-1000mg_REG_SmPC_PF18-0072_clean.docx

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 09 August 2017

File name

PIL_14275_792.pdf

Reasons for updating

  • New PIL for new product

Updated on 09 August 2017

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - pregnancy, breast feeding and fertility

Updated on 06 June 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 11 April 2017

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects

Updated on 11 April 2017

Reasons for updating

  • Improved presentation of PIL

Updated on 30 August 2016

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 01 September 2015

Reasons for updating

  • Change to side-effects
  • Change to MA holder contact details

Updated on 19 June 2014

Reasons for updating

  • Change to side-effects

Updated on 11 October 2013

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to dosage and administration

Updated on 05 December 2012

Reasons for updating

  • Change to, or new use for medicine
  • Change to side-effects

Updated on 08 November 2012

Reasons for updating

  • Change to side-effects
  • Change to improve clarity and readability

Updated on 03 January 2012

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 18 August 2011

Reasons for updating

  • Change to further information section

Updated on 22 September 2010

Reasons for updating

  • Change to side-effects

Updated on 09 June 2010

Reasons for updating

  • Change to MA holder contact details

Updated on 08 October 2009

Reasons for updating

  • Change to side-effects

Updated on 05 May 2009

Reasons for updating

  • New PIL for new product